Antengene licenses ATG-106 to K2 Therapeutics for $20M upfront

Markets Investing.com By Investing.com 22 Jun 2026 00:37 1 min read

Antengene licenses ATG-106 to K2 Therapeutics for $20M upfront

Antengene licenses ATG-106 to K2 Therapeutics for $20M upfront

Antengene licenses ATG-106 to K2 Therapeutics for $20M upfront

Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.